SCHEMBL10330767

SCHEMBL10330767

Cc1nc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 8/20 0.59
TOP2B Q02880 8/20 0.59
DPP4 P27487 6/20 0.56
CHRM2 P08172 1/20 0.54
DRD1 P21728 1/20 0.54
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 3/20 0.50
HSD17B10 Q99714 3/20 0.50
HPGD P15428 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
MAPT P10636 1/20 0.50
ABCC4 O15439 1/20 0.50
KCNH2 Q12809 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9437304 0.88 TOP2A (0.58) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL5142702 0.88 DPP4 (0.58) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL4747719 0.86 TOP2A (0.47) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL500472 0.85 DPP4 (0.57) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL10876232 0.85 DPP4 (0.59) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL14472239 0.85 DPP4 (0.56) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL13014061 0.85 DPP4 (0.54) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL14143514 0.85 DPP4 (0.54) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL17537044 0.83 DPP4 (0.56) TOP2ATOP2BDPP4CHRM2DRD1
SCHEMBL10876616 0.82 DPP4 (0.56) TOP2ATOP2BDPP4CHRM2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861401-B1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2015-11-18 EP disclosed
US-8222407-B2 Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-07-17 US disclosed
US-8222407-B2 Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-07-17 US disclosed
US-20100197909-A1 MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-08-05 US disclosed
US-20100197909-A1 MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-08-05 US disclosed
US-7732612-B2 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones JANSSEN PHARMACEUTICA, N.V. (BE) 2010-06-08 US disclosed
US-7687629-B2 Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate LG LIFE SCIENCES LTD. (KR) 2010-03-30 US disclosed
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2009-06-18 US disclosed
US-20070282107-A1 New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate LG LIFE SCIENCES LTD. 2007-12-06 US disclosed
US-7271272-B2 Process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate LG LIFE SCIENCES LTD. (KR) 2007-09-18 US disclosed
US-7232907-B2 Process for production of naphthyridine-3-carboxylic acid derivatives LG LIFE SCIENCES LIMITED (KR) 2007-06-19 US disclosed
US-7199242-B2 Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof LG LIFE SCIENCES LIMITED (KR) 2007-04-03 US disclosed
US-7179805-B2 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282107-A1 New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate MLN, AAAS, ACMSD TOP2A 69/4885TOP2B 46/4885DPP4 104/4885
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES NQO2, QRFPR, NQO1 TOP2A 389/4885TOP2B 359/4885DPP4 1254/4885
US-20100197909-A1 MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION PELP1, MLN, SND1 TOP2A 3897/4885TOP2B 4117/4885DPP4 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.